Welcome to our dedicated page for Artelo Biosciences news (Ticker: ARTL), a resource for investors and traders seeking the latest updates and insights on Artelo Biosciences stock.
Artelo Biosciences, Inc. (NASDAQ: ARTL) is a clinical-stage pharmaceutical company developing proprietary therapeutics that modulate lipid-signaling pathways, including the endocannabinoid system. The ARTL news feed on Stock Titan aggregates company announcements, scientific updates, financing transactions, and regulatory disclosures that shape the outlook for its drug development programs.
Investors and observers following Artelo’s news can track progress across a diversified pipeline that includes ART27.13 for cancer anorexia and weight loss, ART26.12 as a Fatty Acid Binding Protein 5 (FABP5) inhibitor for chemotherapy-induced peripheral neuropathy and other potential indications, and ART12.11, a patented cocrystal composition of cannabidiol (CBD) and tetramethylpyrazine (TMP). Company press releases highlight interim clinical data from the Cancer Appetite Recovery Study (CAReS), Phase 1 results for ART26.12, and preclinical findings supporting the therapeutic potential of FABP inhibition and pharmaceutical-grade CBD formulations.
The ARTL news stream also features peer-reviewed publication announcements, conference presentations at oncology and cannabinoid-focused meetings, and corporate developments such as executive appointments, cooperation agreements with shareholders, and capital-raising activities via public offerings, private placements, and at-the-market programs. Regulatory and listing-related updates, including communications about Nasdaq listing compliance, are disclosed through Form 8-K filings and associated press releases.
By reviewing Artelo Biosciences news on this page, readers can monitor key milestones in its clinical trials, scientific validation of its FABP and CBD platforms, and corporate actions that influence its financial and strategic position. Bookmark this feed to follow how Artelo’s lipid-signaling and endocannabinoid-targeted programs evolve through clinical, scientific, and capital markets events over time.
Artelo Biosciences (Nasdaq: ARTL) has initiated the Phase 2a segment of its Cancer Appetite Recovery Study (CAReS) for ART27.13, aimed at treating cancer-related anorexia and weight loss. The study will assess 40 patients, using a 3:1 ratio for ART27.13 versus placebo over 12 weeks. Following positive safety outcomes in Phase 1b, a dose of 650 micrograms will be administered. About 18 clinical sites across five countries will participate. ART27.13 targets cannabinoid receptors and has shown potential for increasing appetite without adverse central nervous system effects. The global market for addressing anorexia in cancer patients is estimated over $2 billion. The company hopes to complete patient enrollment by mid-2024.
Artelo Biosciences (Nasdaq: ARTL) reported significant developments for the fiscal year ending December 31, 2022, highlighting $17.5 million in cash and marketable securities available to support operations into the latter half of 2024. The CEO emphasized advances in their clinical trial for ART27.13, aimed at treating cancer-related anorexia, with enrollment completion of all cohorts and the next Phase 2a stage anticipated to start in April 2023. The company also noted a net loss of $10.1 million for the year and a strategic full pipeline development, including research on their lead fatty acid binding protein inhibitor.
Artelo Biosciences (NASDAQ:ARTL), a clinical-stage pharmaceutical company, will present at the MicroCap Rodeo's Third Annual Winter Wonderland Best Ideas Virtual Investor Conference from February 21-24, 2023. CEO Gregory D. Gorgas is scheduled to present on February 22 at 9:00 a.m. Eastern Time, with a live webcast available for replay. The conference highlights 37 companies recommended by qualified institutional investors, showcasing top investment ideas. Artelo is focused on developing therapies for conditions including cancer, pain, and neurological disorders. For more details or to schedule meetings, interested parties can contact the company.
Artelo Biosciences (ARTL) has completed enrollment in the final cohort of its Phase 1b Cancer Appetite Recovery Study (CAReS) for ART27.13, aimed at evaluating safety and efficacy in cancer patients experiencing anorexia. The highest permissible dose of 650 micrograms has been administered, with preliminary results indicating a well-tolerated safety profile and mild adverse reactions. The company anticipates progressing to the randomized Phase 2a stage to assess the drug's effectiveness, targeting a market projected to exceed $2 billion for cancer-related appetite loss treatments. Artelo expresses gratitude to participants and research teams for overcoming enrollment challenges.
Artelo Biosciences, a clinical-stage pharmaceutical company, announced that CEO Gregory D. Gorgas will present at the Sequire Biotechnology Conference on February 2, 2023, at 1:00 PM ET. The presentation will focus on the Company’s ongoing Cancer Appetite Recovery Study (CAReS). The biotechnology sector is projected to reach $727 billion by 2025, highlighting its growth potential. This event, hosted virtually, aims to connect public biotech companies with investors. Artelo is dedicated to developing innovative treatments targeting significant unmet needs related to cancer and other conditions. More details can be found at artelobio.com.
Artelo Biosciences (Nasdaq: ARTL) reported financial results for the quarter ending September 30, 2022, showing a net loss of approximately $2.3 million, or $0.82 per share, compared to a loss of $2.2 million or $1.37 per share for the same period in 2021. As of September 30, 2022, the company had $19.5 million in cash and investments, expected to support operations through mid-2024. Enrollment for the Phase 2a Cancer Appetite Recovery Study (CAReS) is set to begin near year-end, following positive Phase 1b results.
Artelo also highlighted promising non-clinical data for its FABP5 platform, indicating potential treatments for both pain and anxiety.
Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company, will present at the 2022 Ladenburg Thalmann Healthcare Conference on September 29, 2022, in New York City. CEO Gregory D. Gorgas will speak at 8:30 a.m. ET, and one-on-one meetings will be available throughout the event. The presentation will also be streamed online. Artelo focuses on developing treatments for cancer, pain, and neurological conditions through lipid-signaling pathways, aiming to address significant unmet medical needs.
Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company, announced that CEO Gregory D. Gorgas will present at the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. The event includes virtual and in-person attendance at the Lotte New York Palace Hotel. The presentation will be available on-demand starting September 12 at 7:00 AM ET. Artelo focuses on developing treatments for cancer, pain, and neurological conditions through lipid-signaling pathway modulation.
Artelo Biosciences (ARTL) recently announced pre-clinical findings suggesting that its fatty acid binding protein 5 (FABP5) inhibitor may effectively reduce anxiety behaviors in key brain areas. These results indicate that FABP5 modulation could serve as a new target for developing anxiety treatments, including potential therapies for post-traumatic stress disorder (PTSD). Published in Cerebral Cortex, the study led by researchers from the University of Western Ontario demonstrates the role of the CB2 receptor in managing fear and anxiety, underscoring the importance of this research.
Artelo Biosciences (Nasdaq: ARTL) announced advancements in its clinical programs with the CAReS Study for ART27.13, targeting cancer-related anorexia, progressing to a fourth cohort due to its well-tolerated safety profile. The company also reported a net loss of $2.4 million for Q2 2022 and a cash balance of $21.3 million, expected to fund operations into 2023. A 15-for-1 reverse stock split will take effect on August 10, 2022, aimed at enhancing stock marketability and compliance with Nasdaq requirements.